Fabio Pucci, Ph.D.

Fabio Pucci is an investor at Leaps by Bayer, the investment arm of the global life sciences company Bayer. He is responsible for healthcare focused investment across a wide spectrum of therapeutic modalities and indications. Fabio currently serves as board director or observer for Capstan, Immunitas, Indapta, Kojin, Mozart and, previously, for Hemab. Prior to Leaps by Bayer, Fabio worked at RA Capital, a biotech multistage investment fund, and at the Francis Crick Institute in London as a cancer researcher. Fabio obtained his PhD from the Wellcome Trust Centre for Cell Biology and his MBA from the London Business School.